Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | KCNA3 | P22001 | 16/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3455503 | 0.88 | MEN1 (1.00) | MEN1KMT2AALDH1A1KCNA3 | |
| SCHEMBL31685209 | 0.87 | KCNA3 (1.00) | MEN1KMT2AALDH1A1KCNA3 | |
| SCHEMBL1946359 | 0.87 | KCNA3 (1.00) | MEN1KMT2AALDH1A1KCNA3 | |
| SCHEMBL3904049 | 0.87 | MEN1 (0.97) | MEN1KMT2AALDH1A1KCNA3 | |
| SCHEMBL13154750 | 0.84 | KCNA3 (0.73) | MEN1KMT2AALDH1A1KCNA3 | |
| SCHEMBL13154760 | 0.83 | KCNA3 (0.72) | MEN1KMT2AALDH1A1KCNA3 | |
| SCHEMBL13154740 | 0.82 | KCNA3 (0.70) | MEN1KMT2AALDH1A1KCNA3 | |
| SCHEMBL3897406 | 0.82 | KCNA3 (0.81) | MEN1KMT2AALDH1A1KCNA3 | |
| SCHEMBL2470906 | 0.81 | MEN1 (0.81) | MEN1KMT2AALDH1A1KCNA3 | |
| SCHEMBL13154734 | 0.81 | KCNA3 (0.68) | MEN1KMT2AALDH1A1KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357704-B2 | Fused heterocyclic compounds as inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-8357704-B2 | Fused heterocyclic compounds as inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-20100247534-A1 | FUSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| US-20100247534-A1 | FUSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| US-7772232-B2 | Quinazolinyl compounds as inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772232-B2 | Quinazolinyl compounds as inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1143965-B1 | CARBOCYCLIC POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-6632836-B1 | To treat autoimmune disorders, cardiac arrhythmias and the like | MERCK & CO., INC. | 2003-10-14 | — | — | US | disclosed |
| EP-1143965-A4 | CARBOCYCLIC POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1143965-A1 | CARBOCYCLIC POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000025770-A1 | CARBOCYCLIC POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247534-A1 | FUSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNH2, KCNH3, KCNB1 | MEN1 544/4885KMT2A 641/4885ALDH1A1 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.